Company-wide revenue
Reported revenue in 2020 ¥17.82B Reported revenue in 2024 ¥23.27B
- growth amount
- +¥5.45B
- growth annualized
- +6.9%
- growth total
- +30.6%
Japanese company profile · 9273
KOA SHOJI HOLDINGS CO.,LTD.
In its FY2024 public filing, KOA SHOJI HOLDINGS CO.,LTD. reports Pharmaceutical sales, Pharmaceutical Manufacturing and Sales Business. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: コーア商事ホールディングス株式会社
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
KOA SHOJI HOLDINGS CO.,LTD.'s largest reported business by revenue in FY2024 was Pharmaceutical sales.
The business with the highest reported segment profit in FY2024 was Pharmaceutical sales.
FY2024 · fiscal year ended June 2025 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| Pharmaceutical sales | ¥15.93B ↗ | 68.5% | ¥3.22B ↗ |
| Pharmaceutical Manufacturing and Sales Business | ¥8.67B ↗ | 37.3% | ¥2.14B ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2024 · fiscal year ended June 2025. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Pharmaceutical sales
- 原薬販売事業
- Pharmaceutical Manufacturing and Sales Business
- 医薬品製造販売事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- Pharmaceutical sales
- 原薬販売事業
- Pharmaceutical Manufacturing and Sales Business
- 医薬品製造販売事業
- Sales
- 売上高
- Operating profit
- 営業利益
Reported Sales by business over time
Reported Sales by business over time
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Pharmaceutical sales | ¥12.5B | ¥14.72B | ¥16B | ¥15.46B | ¥15.93B |
| Pharmaceutical Manufacturing and Sales Business | ¥7.02B | ¥7.51B | ¥7.89B | ¥8.4B | ¥8.67B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Pharmaceutical sales
Reported revenue in 2020 ¥12.5B Reported revenue in 2024 ¥15.93B
- growth amount
- +¥3.43B
- growth annualized
- +6.2%
- growth total
- +27.4%
View original filing
Pharmaceutical Manufacturing and Sales Business
Reported revenue in 2020 ¥7.02B Reported revenue in 2024 ¥8.67B
- growth amount
- +¥1.65B
- growth annualized
- +5.4%
- growth total
- +23.5%
View original filing
Pharmaceutical Manufacturing and Sales Business
Reported profit margin in 2021 +18.9%
Reported profit margin in 2024 +24.7%
- growth margin points
- +5.7
View original filing
Pharmaceutical sales
Reported profit margin in 2021 +16.2%
Reported profit margin in 2024 +20.2%
- growth margin points
- +3.9
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2024 · fiscal year ended June 2025
The source document may be in Japanese.
Filing ID: S100WRWI
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.